Research programme: menin-MLL inhibitors - Syndax Pharmaceuticals

Drug Profile

Research programme: menin-MLL inhibitors - Syndax Pharmaceuticals

Alternative Names: VTP-50469

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Syndax Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute biphenotypic leukaemia

Most Recent Events

  • 24 Oct 2017 Syndax Pharmaceuticals plans to file an IND application for menin-MLL inhibitors for Leukaemia (Syndax website, October 2017)
  • 18 Oct 2017 Preclinical trials in Leukaemia in USA (PO)
  • 17 Oct 2017 Menin-MLL inhibitors licensed to Syndax Pharmaceuticals worldwide for the treatment of Leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top